Black cohosh is a popular botanical often considered by women seeking support during midlife and menopause. As with any botanical preparation, understanding its potential effects and considerations, including those related to liver health, is an important aspect of informed decision-making.
Concerns about black cohosh and liver function have been raised, prompting investigations into the available evidence. This article aims to provide a balanced overview of what the research suggests about black cohosh’s relationship with liver health, drawing solely from published studies.
Initial Reports and Causality Challenges
Reports of liver issues associated with black cohosh began to emerge, leading to discussions within the scientific community. However, assessing the direct causal link between black cohosh and liver damage has proven complex [1]. Many of these early reports were case studies, which, while valuable for identifying potential issues, do not definitively prove cause and effect on their own [2].
Challenges in determining causality include inconsistencies in the reported cases and the presence of confounding variables that could contribute to liver issues independently of black cohosh use [3]. Factors such as the use of other medications, pre-existing health conditions, and the quality or composition of the black cohosh product itself can make it difficult to isolate black cohosh as the sole cause [3].
Evaluating Causality: Diagnostic Algorithms and Methodologies
To address the complexities of causality, researchers have utilized diagnostic causality algorithms to systematically evaluate suspected cases of black cohosh-related liver issues [3]. These algorithms help to objectively assess the likelihood that a particular substance caused a reported adverse event by considering factors like the timing of exposure, the presence of other potential causes, and the response to discontinuation.
A review of suspected black cohosh hepatotoxicity cases, using a quantitative causality evaluation, indicated varying degrees of probability, with some cases showing a possible or probable link, while others were less clear [4]. This highlights that not all reported cases definitively implicate black cohosh as the cause of liver issues.
Findings from Randomized Controlled Clinical Trials and Meta-Analyses
While case reports raise important questions, randomized controlled clinical trials (RCTs) are often considered the gold standard for evaluating efficacy and safety. A meta-analysis of randomized controlled clinical trials specifically investigating an isopropanolic black cohosh extract (iCR) found no evidence of liver toxicity [5]. This suggests that, within the context of these specific clinical trials, liver issues were not observed.
Further reviews and meta-analyses on the isopropanolic black cohosh extract iCR for menopausal symptoms have continued to update the evidence, supporting its tolerability profile, including with respect to liver function [6]. These comprehensive analyses pool data from multiple studies, providing a broader perspective on potential effects.
Product Variability and Contamination Concerns
One significant challenge in evaluating the safety of black cohosh, including its impact on the liver, is the variability in botanical products. The quality and composition of black cohosh supplements can differ widely between manufacturers [7]. Some products marketed as black cohosh may contain other plant species, or be adulterated, which could introduce different compounds with their own potential effects on the liver [8].
This variability makes it difficult to attribute any observed effects solely to *Cimicifuga racemosa* (black cohosh) itself. The United States Pharmacopeia (USP) has conducted reviews of black cohosh case reports, emphasizing the importance of product authentication and standardization to ensure consumer safety [2].
Overall Perspective on Liver Health and Black Cohosh
The overall evidence concerning black cohosh and liver health is moderate. While early case reports raised concerns and some cases were assessed as possibly or probably linked to black cohosh, robust evidence from meta-analyses of randomized controlled trials using specific standardized black cohosh extracts has not demonstrated a causal link to liver damage [PMID 21228727, PMID 33021111].
It is crucial for individuals considering black cohosh to be aware of the potential for product variability and to choose reputable brands that prioritize quality and purity. The complexity of assessing causality in individual cases means that a definitive statement across all black cohosh products is challenging [1].
References
- Suspected black cohosh hepatotoxicity–challenges and pitfalls of causality assessment. Maturitas, 2009
- United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause (New York, N.Y.), 2008
- Black cohosh and suspected hepatotoxicity: inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm. A critical review. Menopause (New York, N.Y.), 2010
- Black cohosh hepatotoxicity: quantitative causality evaluation in nine suspected cases. Menopause (New York, N.Y.), 2009
- Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of randomized controlled clinical trials for isopropanolic black cohosh extract. Menopause (New York, N.Y.), 2011
- Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms – an update on the evidence. Climacteric : the journal of the International Menopause Society, 2021
- Black Cohosh. 2012
- Herb-Induced Liver Injury by Cimicifuga racemosa and Thuja occidentalis Herbal Medications for Fertility. Case reports in gastrointestinal medicine, 2021
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
